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BACKGROUND: Increased epidermal growth factor receptor (EGF receptor) expression has been noted in vari-
ous cancers and has become a useful target for therapeutic interventions. Small studies from Asia and Australia 
have demonstrated EGFR over-expression in gallbladder cancer. We sought to evaluate the expression of EGFR 
in a series of 16 gallbladder cancer patients from North America. 
METHODS: Using tumor registry data, we identified 16 patients diagnosed with gall bladder carcinoma at our 
medical center between the years of 1998 and 2005. We performed a retrospective review of these patients’ charts, 
obtained cell blocks from pathology archives and stained for EGFR and Her2/neu. 
RESULTS: Fifteen of sixteen patients were noted to over-express EGFR. Three were determined 1+, nine were 2+ 
and three were 3+. Eight patients had poorly differentiated adenocarcinoma, six had moderately differentiated 
and two had well-differentiated tumors. In this small series, there was a trend toward shorter survival and more 
poorly differentiated tumors in patients with greater intensity of EGFR expression. One patient was EGFR nega-
tive but 3+ for erb-2/Her 2-neu expression. No patient co-expressed EGFR and Her-2-neu. Median survival of 
patients in this series was 17 months. 
CONCLUSION: In view of our observations confirming the over-expression of EGFR in our patient population in 
North America, and the recent success of EGFR targeted therapies in other solid tumors that over-express EGFR, 
it may now be appropriate to evaluate agents targeting this pathway either as single agents or in combination 
with standard chemotherapy. 
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Introduction 
Approximately 5000 cases of gallbladder cancer 
are diagnosed in the United States per year. Higher 
rates are seen in Latin American countries such as 
Mexico, Chile and Bolivia, roughly correlating with the 
higher incidence of cholelithiasis. Various chemo-
therapy agents, including 5-FU and Gemcitabine, have 
been evaluated for the management advanced disease 
but thus far results have been disappointing [1-4]. 
5 FU plus LV has been the backbone of random-
ized clinical trials done in the past, demonstrating a RR 
of 32% and OS of 6months.[5] Combination therapy 
with 5FU and cisplatin have shown RRs of 10%–40% 
and median OS better than those observed with 5-FU 
alone.[5-12] Single agent gemcitabine has been exten-
sively evaluated in patients with metastatic biliary 
tract tumors with RRs in the range of 0%–30%, with 
median OS times in the range of 5–14 months. 
[13-18]Gemcitabine combinations with cisplatin, ox-
a l i p l a t i n  o r  c a p e c i t a b i n e  h a v e  b e e n  t e s t e d  i n  s e v e r a l  
clinical trials, which have demonstrated RRs 21%–53% 
and median OS times 5–15 months; these results are 
somewhat better than those from single-agent gem-
citabine studies.[19-23] A pooled analysis of 112 trial 
using gemcitabine-based combination regimens con-
firmed superiority to single agent therapy. However 
the outcomes are still dismal with the pressing need 
for development of newer therapies.[1, 24, 25] 
Increased epidermal growth factor receptor (EGF 
receptor) expression has been noted in various cancers 
such as colon, squamous cell of the head and neck, 
non-small cell lung and breast cancers. Several small 
studies from Asia, Europe and Australia have exam-
ined the expression of EGFR in gallbladder can-
cer.[26-30] The epidermal growth factor receptor is one 
of many transmembrane protein kinases that are in-
volved in signal transduction affecting cellular activi-Int. J. Med. Sci. 2008, 5 
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ties such as metabolism, transcription, cell-cycle pro-
gression, apoptosis and differentiation.[31] These 
processes are tightly controlled, but when protein 
kinase activity is deregulated, malignant transforma-
tion may occur. [32] Among the various mechanisms 
of increased EGFR activation, is receptor 
over-expression, gene amplification and the loss of 
inhibitory signals. Activation of EGFR results in 
phosphorylation of intracellular substrates down-
stream and the subsequent activation of mitotic path-
ways. [32] 
The improved understanding of EGFR’s role in 
oncogenesis has made it an attractive target for thera-
peutic intervention in several cancers. Clinical and 
preclinical data exist utilizing this target in colon can-
cer, squamous cell carcinoma of the head and neck, 
non-small cell lung cancer and breast cancer. [33-41] 
Likewise, the over-expression of EGFR on gallbladder 
carcinoma may have direct clinical implications with 
an alternative management strategy for the manage-
ment of this difficult disease. [42, 43] In our study, we 
have gathered the data showing over-expression of 
EGFR in gallbladder cancer cases in North America. 
Materials and Methods 
Data Retrieval  
Institutional Review Board approval was ob-
tained. Tumor registry data identified patients diag-
nosed with gall bladder carcinoma at a single institu-
tion between the years of 1998 and 2005. We per-
formed a retrospective review of these consecutive 
patients’ charts and obtained the following informa-
tion: biopsy site, stage at diagnosis, treatment modali-
ties, survival, and tumor grade. Cell blocks were then 
obtained from pathology archives and stained for 
EGFR and Her2/neu as described below. 
Methods for EGFR and Her 2/neu staining 
Serial 4µm sections were cut from the cell block. 
Slides were then placed in xylene for 15 minutes for 
deparaffinization. Dehydration was performed by 
steps of graded alcohol. Tap water was used for rehy-
dration. Slides stained with Her-2/neu (prediluted, 
monoclonal, clone CB11, Carpinteria, CA) were then 
pretreated for antigen retrieval by microwaving for 30 
minutes using citrate buffer, p H  6 .  T h e y  w e r e  t h e n  
stained using the Ventana Nexus autostainer. Slides 
stained with EGFR (prediluted, monoclonal, clone 
2-18C9, Carpinteria, CA) were not pretreated for anti-
gen retrieval and were stained using the Ventana 
autostainer.  
Two observers who were blinded to the histologic 
diagnosis interpreted the slides. Cell membrane stain-
ing was used to assess positivity for EGFR and Her 
2/neu. In each case, the intensity of the staining (0- 
negative to 3- strong) was determined. (Figure 1a-c).  
 
 
Figure 1. EGFR Staining. 
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The staining pattern for Her2-neu was deter-
mined as follows: Score 0= no staining is observed; 
Score 1+= faint membrane staining in more than 10% 
of tumor cells in part of the cell membrane; score 2+= 
weak to moderate complete membrane staining in 
over 10% of tumor cells; score 3+= strong complete 
membrane staining in over 10% of tumor cells.  
The staining pattern for EGFR was determined as 
follows: Score 0= no staining is observed; Score 1+= 
faint membrane staining in more than 1% of tumor 
cells in part of the cell membrane; score 2+= weak to 
moderate complete membrane staining in over 1% of 
tumor cells; Score 3+=strong complete membrane 
staining in over 1% of tumor cells.  
Results 
In our series of sixteen patients, fifteen were 
noted to over-express EGFR (Table 1). Three were de-
termined 1+, nine were 2+ and three were 3+. Eight 
patients had poorly differentiated adenocarcinoma, six 
had moderately differentiated and two had 
well-differentiated tumors. One patient was EGFR 
negative but 3+ for erb-2/Her 2-neu expression. Nine 
of 16 patients underwent surgical intervention alone, 
three underwent chemotherapy alone, two underwent 
both surgery and chemotherapy and two underwent 
surgery, chemotherapy and radiation therapy. Staging 
distribution was as follows: stage I: 12.5%(n=2); stage 
II: 37.5%(n=6); stage III: 12.5% (n=2); stage IV: 
37.5%(n=6).  
Table 1. Results 
Patient    Age  Sex Stage  Biopsy Site  Rx modality Survival  differentiation/Grad  Erb-B-2/Her 2-neu  EGFR 
1  83  M  II  gallbladder  S  40 months  poor diff adenocarcinom  3+  negative
2  76  F  II  gallbladder  S  12 months  mod diff adenocarcinom  negative  1+ 
3  61  F  IV  gallbladder  S  17 months  well-diff adenocarcinom  negative  1+ 
4  62  F  IV  peritoneum  C  9 months  mod diff adenocarcinom  negative  1+ 
5  54  F  IV  liver  C  10.5 months  mod diff adenocarcinom  negative  2+ 
6  77  F  I  gallbladder  S   28 months (alive)  poor diff adenocarcinom  negative  2+ 
7  65  F  II  gallbladder  S  11 months  mod diff adenocarcinom  negative  2+ 
8  70  F  II  gallbladder  S,C,R  25 months (alive)  well-diff mucinous adenocarc  negative  2+ 
9  55  F  IV  omentum  C  4 months  poor diff adenocarcinom  negative  2+ 
10  63  M  II  gallbladder  S  33 months(alive)  mod diff adenocarcinom  negative  2+ 
11  71  F  III  gallbladder  S  50 months (alive)  poor diff adenocarcinom negative  2+ 
12  68  F  II  gallbladder  S,R,C  19 months  poor diff adenocarcinom  negative  2+ 
13  75  F  IV  peritoneum  S,C  27 months  mod diff adenocarcinom  negative  2+ 
14  80  F  I  gallbladder  S  17 months  poor diff adenocarcinom  negative  3+ 
15  74  F  IV  gallbladder  S,C   3.5 months  poor diff adenocarcinom  negative  3+ 
16 46 F  III  gallbladder  S  2.5  months  poor diff adenocarcinom  negative  3+ 
S=surgery, C=chemotherapy, R=radiation 
 
We evaluated a possible correlation between the 
level of differentiation and intensity of EGFR expres-
sion. The three patients with 1+ expression had 
well-differentiated (one patient) and moderately dif-
ferentiated (two patients) adenocarcinoma. Con-
versely, all three of the 3+ EGFR patients had tumors 
of the poorly differentiated type. The nine patients 
with 2+ EGFR was a mix of the former groups (one 
well-differentiated, four moderately differentiated and 
four poorly differentiated). This suggests an inverse 
relationship between differentiation and EGFR ex-
pression. Median survival of the 3+ patients was 3.5 
months compared to 17 months overall.  
Although our sample size is small, our data above 
also suggests an inverse relationship between EGFR 
expression intensity and survival. The patient with 
stage I disease with 3+ EGFR staining had a survival of 
17 months versus the other stage I patient in our sam-
ple, who had 2+ EGFR staining, and is alive at 28 
months follow-up. The patient with stage IV disease 
expressing 3+EGFR, had a survival of 3.5 months 
compared to the median survival of 10.5 months for 
stage IV patients with 1+ and 2+ staining. In summary, 
the 3+ patients had a substantially shorter survival 
when compared with less intense EGFR expression 
patients of similar stage.  Int. J. Med. Sci. 2008, 5 
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Discussion 
Background of EGFR 
Epidermal growth factor receptor is a protein 
kinase receptor involved in the signal transduction 
affecting cellular activities such as metabolism, tran-
scription, cell-cycle progression, apoptosis and differ-
entiation. The two major subsets of drugs that inhibit 
EGF receptors are monoclonal antibodies and small 
molecules. The monoclonal antibodies prevent ligand 
binding and activation of the EGFR. One agent of this 
type is cetuximab, which has shown clinical efficacy in 
colon, [31, 32] and head and neck cancers. [31] Small 
molecules that target EGFR compete with ATP binding 
to the tyrosine kinase domain, thereby blocking sig-
naling pathways.[32] Examples of drugs of this type 
are gefitinib and erlotinib. Erlotinib has shown activity 
against non-small cell lung and pancreatic cancers.  
EGFR Expression in our sample of Gallbladder cancer 
patients 
As with the available published data from Asia 
and Australia, we found a predominance of EGFR 
over-expression in our gallbladder cancer specimens. 
In our sample of 16 patients, only one patient (6.3%) 
did not have over-expression of EGFR. Nine pa-
tients(56.3%) were 2+ and three(18.3%) were 3+ in 
immunohistochemical staining. All fifteen of the pa-
tients expressing EGFR were negative for Erb-B-2/Her 
2-neu. Conversely, the single patient that expressed 
Erb-B-2/Her 2-neu was 3+ intensity, and was negative 
for EGFR. We found it interesting that these two re-
ceptors, both of the erb-B family, have no 
co-expression in any of our patients. 
As shown in the results, a disproportionate 
number of patients with 3+ EGFR expression had 
poorly differentiated tumors. Conversely, the patients 
with 1+ EGFR expression seemed to have proportion-
ally higher numbers of patients with moderate or 
well-differentiated tumors. This suggests an inverse 
relationship between differentiation and EGFR ex-
pression. Assuming that poorly differentiated tumors 
behave more aggressively, intensity of EGFR expres-
sion may correlate with aggressiveness of disease.  
This hypothesis is further supported by the ex-
amining the EGFR expression relating to survival. 
Stage for stage, the patients with greater EGFR inten-
sity had shorter survival therefore suggesting an in-
verse relationship between EGFR expression intensity 
and survival. Although the number of patients is few, 
this is a consistent pattern throughout our sample. The 
patient with stage I disease with 3+ EGFR staining had 
a survival of 17 months versus the other stage I patient 
in our sample, who had 2+ EGFR staining, and is alive 
at 28 months follow-up. The patient with stage IV 
disease expressing 3+EGFR, had a survival of 3.5 
months compared to the median survival of 10.5 
months for stage IV patients with 1+ and 2+ staining. 
In summary, the 3+ patients had a substantially shorter 
survival when compared with less intense EGFR ex-
pression patients of similar stage.  
Previous studies of EGFR Expression in Biliary Tu-
mors 
A study from MD Anderson demonstrated that 
constitutive expression of ErbB-2 in mice resulted in 
development of gallbladder cancer. [44]Several small 
studies, mostly from Asia, have complemented this 
work by examining the level of expression of EGFR in 
biliary tumors (Table 2). These few studies demon-
strated a significant and consistent over-expression of 
epithelial growth factor receptor in biliary tumors. The 
largest such study was published by Zhou et al from 
China.[26] Zhou compared EGFR expression in normal 
gallbladder specimens (10 specimen) with gallbladder 
carcinoma specimen (41 specimens) and hyperplastic 
tissue specimens (26) using immunohistochemistry. 
EGFR over-expression was found to be 71% in the car-
cinoma specimens as compared to 0% of the normal 
gallbladder specimens. Lee et al performed immuno-
histochemistry stains for EGFR on 13 gallbladder can-
cer specimens from Australia.[29] 100% of the gall-
bladder cancer specimens were found to stain strongly 
positive for EGFR.   
Table 2. EGFR expression in Biliary Tumors. 
Study N  Immunoreactivity(%) 
Lee et al.[29]  Gallbladder-13 
Biliary duct-7 
100% 
86% 
Kim et al.[52]  Biliary duct-20  25% 
Zhou et al.[26]  Gallbladder-41  71% 
 
 
Table 3. Single agent Gemcitabine. 
Study N  Response 
Rate (%) 
Stable 
Disease 
Time to 
Progres-
sion 
(months)
Median 
Overall 
Survival 
Eng et al.[53]  14  0%  13%  9 months 5 months 
Mehrotra et al[54]  12  0%  75%  3 months  6 months 
Funakoshi et al.[55] 40  17.5%    2.6 
months 
7.6 months 
Tsavaris et al [56]  30  30%    7 months 17 months 
(Gallblad-
der) 
11 months 
(biliary 
duct) 
Gallardo et al.[57]  26  36%  36.7%     
Park et al.[58]  23  26%  39%  8.1 
months 
13.1 months
Kubicka et al.[17]  23  30%       
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Table 4. Gemcitabine Combinations. 
Study   Treatment  N  Response 
Rate (%) 
Median 
Time to 
Progression 
Median 
Overall 
Survival 
Doval et al 
[59] 
Gemcitabine 
+ cisplatin 
39  37%  4.5 months  5 months
Park et 
al.[58] 
Gemcitabine 
+ cisplatin 
35 17%  3.5  months  8.3 
months 
Malik et 
al.[60] 
Gemcitabine 
+ cisplatin 
11 64%  6.5  months  10 
months 
Reyes-Vidal 
et al [61] 
Gemcitabine 
+ cisplatin 
44 48%    7  months
Tan et al.[22] Gemcitabine 
+ carboplatin 
13 31%     
Knox et 
al.[3] 
Gemcitabine 
+ Capecit-
abine 
45 31%  7  months  14 
months 
Chang et al 
[23] 
Gemcitabine 
+ Capecit-
abine 
34 12%  2.6  months  7.8 
months 
Verderame 
et al [24] 
Gemcitabine 
+ 
Oxaliplatin 
24 50%    12 
months 
Wagner et al 
[25] 
Gemcitabine 
+ Oxaliplatin 
+ 
CI 5-FU 
35     9.9 
months 
NCCTG [26] Gemcitabine 
+ 
CI 5-FU/LV 
42 9.5%  4.6  months   9.7 
months 
Knox [27] Gemcitabine 
+ 
CI 5-FU/LV 
27 33%  3.7  months  5.3 
months 
Knox et 
al.[3] 
Gemcitabine 
+ Capecit-
abine 
45 31%  7  months  14 
months 
Table 5. Non-Gemcitabine Regimens. 
Study Treatment  N  Response  Rate 
(%) 
Romano et al[62]   Cisplatin + iri-
notecan 
16 37% 
Nehls et al.[63]  Capecitabine + 
Oxaliplatin 
27 27% 
Glover et al.[64]  Capecitabine + 
Oxaliplatin 
21 19% 
Sanz-Altamira[65] Carboplatin  + 
5-FU/LV 
14 21% 
 
Current studies in EGFR related therapy of Gallblad-
der Cancer  
Several trials have been undertaken in the past 
investigating chemotherapy for advanced biliary can-
cers, including cancer of the gallbladder. Many of these 
trials involved gemcitabine, either as a single agent 
(table 3) or in combination with other chemotherapies 
(table 4).[1, 2] Other trials have looked at non gemcit-
abine based combination therapies (table 5). The re-
sponse rates have been between 21%–53% and median 
OS times 5–15 months.[1] With limited improvement 
in responses and survival with the combination 
chemotherapies, the focus is now on evolution of 
newer targeted therapies.  
Several studies targeting the EGFR pathway have 
been undertaken. In a phase II study of 42 patients 
with biliary tract cancer treated with single-agent er-
lotinib, Philip et al. demonstrated a 17% 6-month pro-
gression-free survival (PFS) rate; three patients had 
partial responses (PRs) as determined by the Response 
Evaluation Criteria in Solid Tumors. Of these patients, 
57% had received first line chemotherapy. [45] In this 
study,  EGFR  mutation status was not tested, and 
therefore it is unknown if the response correlated with 
EGFR mutation status. There is a possibility that the 
population of patients with the EGFR mutation might 
have a significant benefit from EGFR inhibition ther-
apy, along the lines of non-small cell lung cancer pa-
tients. [2, 46] 
Efficacy of cetuximab, in biliary tract and gall-
bladder cancers, in combination with either Gemcit-
abine or gemcitabine and oxaliplatin have been dem-
onstrated in two studies [42, 43]. Lapatinib, a dual 
EGFR-1and humanepidermal growth factor receptor 
(HER)-2/Neu inhibitor, was tested in a phase I trial in 
seven patients with biliary tract cancer. [47] 
In a recently completed phase II study, patients 
with locally advanced/metastatic cholangiocarcinoma 
or gallbladder cancer were given cetuximab 500 
mg/m² on day 1 followed by 1,000mg/m² gemcitabine 
(day 1) and 100mg/m² oxaliplatin on day 2 every sec-
ond week. The primary endpoint was response rate; 
secondary endpoints were toxicity, progression free 
and overall survival. The overall response rate of 19 
evaluable patients was 58%, including one patient with 
a complete response. Six patients (32%) achieved stable 
disease and 2 patients (11%) progressed under che-
motherapy after a median of 6.5 cycles (SD ± 2.8). The 
response significantly correlated with the grade of 
acne-like rash (p < 0.002). Six initially unresectable 
patients underwent a curative resection after major 
response was observed (32%). The median PFS was 9.0 
months (95% CI 3.1-14.9). Four patients are currently 
without evidence of disease after a median follow-up 
of 6.3 months post-liver resection[42]. Bevacizumab 
and sorafenib are also under investigation for treat-
ment of both these cancers.[48] [49] 
The finding of over-expression of EGFR in our 
patient population in North America further 
strengthens the rationale in targeting this pathway in 
gallbladder cancer [35, 38, 40, 41]. Additional clinical 
trials are underway exploring the role of EGFR inhibi-
tion in this malignancy. Decreased response to EGFR 
inhibitors has been reported in Kras mutant patients in 
colorectal cancer[39-41]. In this context, Kras mutation 
status in patients with biliary tract and gallbladder 
warrants further investigation as use of EGFR inhibi-
tors grows. [50, 51]   Int. J. Med. Sci. 2008, 5 
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